HARP Stock - Harpoon Therapeutics, Inc.
Unlock GoAI Insights for HARP
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | $31.91M | $23.65M | $17.44M | $5.78M | $4.75M |
| Gross Profit | $28.82M | $21.01M | $17.44M | $5.78M | $4.75M |
| Gross Margin | 90.3% | 88.8% | 100.0% | 100.0% | 100.0% |
| Operating Income | $-68,325,000 | $-116,751,000 | $-51,331,000 | $-58,206,000 | $-27,724,000 |
| Net Income | $-67,137,000 | $-166,435,000 | $-46,377,000 | $-51,996,000 | $-27,366,000 |
| Net Margin | -210.4% | -703.6% | -265.9% | -900.1% | -576.1% |
| EPS | $-20.24 | $-51.57 | $-18.52 | $-23.91 | $-11.45 |
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian and pancreatic cancer, and other mesothelin-expressing tumors. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| January 5th 2024 | Oppenheimer | Initiation | Outperform | $23 |
| November 20th 2023 | TD Cowen | Initiation | Outperform | - |
| July 6th 2022 | Canaccord Genuity | Resumed | Buy | $16 |
Earnings History & Surprises
HARPEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2024 | May 9, 2024 | — | — | — | — |
Q1 2024 | Mar 25, 2024 | $-0.50 | $-5.50 | -1000.0% | ✗ MISS |
Q4 2023 | Nov 13, 2023 | $-3.09 | $-0.46 | +85.1% | ✓ BEAT |
Q3 2023 | Aug 9, 2023 | $-4.30 | $0.30 | +107.0% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-4.20 | $-3.10 | +26.2% | ✓ BEAT |
Q1 2023 | Mar 27, 2023 | $-4.30 | $-5.50 | -27.9% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-6.00 | $-3.50 | +41.7% | ✓ BEAT |
Q3 2022 | Aug 10, 2022 | $-5.50 | $-5.30 | +3.6% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-4.80 | $-6.20 | -29.2% | ✗ MISS |
Q1 2022 | Mar 10, 2022 | $-4.60 | $-6.60 | -43.5% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-5.20 | $-5.10 | +1.9% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-4.50 | $-5.20 | -15.6% | ✗ MISS |
Q2 2021 | May 6, 2021 | $-4.30 | $-3.70 | +14.0% | ✓ BEAT |
Q1 2021 | Mar 10, 2021 | $-5.80 | $-4.50 | +22.4% | ✓ BEAT |
Q4 2020 | Nov 4, 2020 | $-5.50 | $-5.30 | +3.6% | ✓ BEAT |
Q3 2020 | Aug 5, 2020 | $-4.80 | $-5.10 | -6.2% | ✗ MISS |
Q2 2020 | May 6, 2020 | $-3.80 | $-5.10 | -34.2% | ✗ MISS |
Q1 2020 | Mar 12, 2020 | $-5.10 | $-5.80 | -13.7% | ✗ MISS |
Q4 2019 | Nov 6, 2019 | $-5.60 | $-6.50 | -16.1% | ✗ MISS |
Q3 2019 | Aug 5, 2019 | $-6.50 | $-4.90 | +24.6% | ✓ BEAT |
Latest News
Frequently Asked Questions about HARP
What is HARP's current stock price?
What is the analyst price target for HARP?
What sector is Harpoon Therapeutics, Inc. in?
What is HARP's market cap?
Does HARP pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to HARP for comparison